Paromomycin targets HDAC1-mediated SUMOylation and IGF1R translocation in glioblastoma
ObjectiveThis study investigates the effects of Paromomycin on SUMOylation-related pathways in glioblastoma (GBM), specifically targeting HDAC1 inhibition.MethodsUsing TCGA and GTEx datasets, we identified SUMOylation-related genes associated with GBM prognosis. Molecular docking analysis suggested...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1490878/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850105416671821824 |
|---|---|
| author | Zhong Min Yuejie Guo Luo Ning |
| author_facet | Zhong Min Yuejie Guo Luo Ning |
| author_sort | Zhong Min |
| collection | DOAJ |
| description | ObjectiveThis study investigates the effects of Paromomycin on SUMOylation-related pathways in glioblastoma (GBM), specifically targeting HDAC1 inhibition.MethodsUsing TCGA and GTEx datasets, we identified SUMOylation-related genes associated with GBM prognosis. Molecular docking analysis suggested Paromomycin as a potential HDAC1 inhibitor. In vitro assays on U-251MG GBM cells were performed to assess Paromomycin’s effects on cell viability, SUMOylation gene expression, and IGF1R translocation using CCK8 assays, qRT-PCR, and immunofluorescence.ResultsParomomycin treatment led to a dose-dependent reduction in GBM cell viability, colony formation, and migration. It modulated SUMO1 expression and decreased IGF1R nuclear translocation, an effect reversible by the HDAC1 inhibitor Trochostatin A (TSA), suggesting Paromomycin’s involvement in SUMO1-regulated pathways.ConclusionThis study highlights Paromomycin’s potential as a therapeutic agent for GBM by targeting HDAC1-mediated SUMOylation pathways and influencing IGF1R translocation, warranting further investigation for its clinical application. |
| format | Article |
| id | doaj-art-d026b39a53c6428cbb4d605e201502e9 |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-d026b39a53c6428cbb4d605e201502e92025-08-20T02:39:05ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-12-011510.3389/fphar.2024.14908781490878Paromomycin targets HDAC1-mediated SUMOylation and IGF1R translocation in glioblastomaZhong MinYuejie GuoLuo NingObjectiveThis study investigates the effects of Paromomycin on SUMOylation-related pathways in glioblastoma (GBM), specifically targeting HDAC1 inhibition.MethodsUsing TCGA and GTEx datasets, we identified SUMOylation-related genes associated with GBM prognosis. Molecular docking analysis suggested Paromomycin as a potential HDAC1 inhibitor. In vitro assays on U-251MG GBM cells were performed to assess Paromomycin’s effects on cell viability, SUMOylation gene expression, and IGF1R translocation using CCK8 assays, qRT-PCR, and immunofluorescence.ResultsParomomycin treatment led to a dose-dependent reduction in GBM cell viability, colony formation, and migration. It modulated SUMO1 expression and decreased IGF1R nuclear translocation, an effect reversible by the HDAC1 inhibitor Trochostatin A (TSA), suggesting Paromomycin’s involvement in SUMO1-regulated pathways.ConclusionThis study highlights Paromomycin’s potential as a therapeutic agent for GBM by targeting HDAC1-mediated SUMOylation pathways and influencing IGF1R translocation, warranting further investigation for its clinical application.https://www.frontiersin.org/articles/10.3389/fphar.2024.1490878/fullglioblastoma multiformeParomomycinHDAC1SUMOylationIGF1Rdrug screening |
| spellingShingle | Zhong Min Yuejie Guo Luo Ning Paromomycin targets HDAC1-mediated SUMOylation and IGF1R translocation in glioblastoma Frontiers in Pharmacology glioblastoma multiforme Paromomycin HDAC1 SUMOylation IGF1R drug screening |
| title | Paromomycin targets HDAC1-mediated SUMOylation and IGF1R translocation in glioblastoma |
| title_full | Paromomycin targets HDAC1-mediated SUMOylation and IGF1R translocation in glioblastoma |
| title_fullStr | Paromomycin targets HDAC1-mediated SUMOylation and IGF1R translocation in glioblastoma |
| title_full_unstemmed | Paromomycin targets HDAC1-mediated SUMOylation and IGF1R translocation in glioblastoma |
| title_short | Paromomycin targets HDAC1-mediated SUMOylation and IGF1R translocation in glioblastoma |
| title_sort | paromomycin targets hdac1 mediated sumoylation and igf1r translocation in glioblastoma |
| topic | glioblastoma multiforme Paromomycin HDAC1 SUMOylation IGF1R drug screening |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1490878/full |
| work_keys_str_mv | AT zhongmin paromomycintargetshdac1mediatedsumoylationandigf1rtranslocationinglioblastoma AT yuejieguo paromomycintargetshdac1mediatedsumoylationandigf1rtranslocationinglioblastoma AT luoning paromomycintargetshdac1mediatedsumoylationandigf1rtranslocationinglioblastoma |